95 / 113
95
[90] P. Wolkenstein, J. Zeller, J. Revuz, E. Ecosse, and A. Leplège, “Quality-of-life impairment in
neurofibromatosis type 1: a cross-sectional study of 128 cases,”
Arch. Dermatol.
, vol. 137, no. 11, pp.
1421–1425, Nov. 2001.
[91] C. Hua, O. Zehou, S. Ducassou, V. Minard-Colin, D. Hamel-Teillac, P. Wolkenstein, and L. Valeyrie-
Allanore, “Sirolimus Improves Pain in NF1 Patients With Severe Plexiform Neurofibromas,”
Pediatrics
,
May 2014.
[92] F. J. DiMario Jr and S. Langshur, “Headaches in patients with neurofibromatosis-1,”
J. Child Neurol.
, vol.
15, no. 4, pp. 235–238, Apr. 2000.
[93]H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher, “Survey of chronic pain in Europe:
prevalence, impact on daily life, and treatment,”
Eur. J. Pain Lond. Engl.
, vol. 10, no. 4, pp. 287–333, May
2006.
[94]D. C. Turk and E.S. Monarch, “Biopsychosocial Perspective on Chronic Pain,” in
Psychological Approaches
to Pain Management: A Practitioner’s Handbook
, D.C. Turk and R.J. Gatchel., Guilford Press, 2002, pp. 3–
29.
[95] B. A. Johnson, B. Macwilliams, J. C. Carey, D. H. Viskochil, J. L. D’Astous, and D. A. Stevenson, “Lower
extremity strength and hopping and jumping ground reaction forces in children with neurofibromatosis
type 1,”
Hum. Mov. Sci.
, vol. 31, no. 1, pp. 247–254, Feb. 2012.
[96] Vakgroep Sociale Geneeskunde, Onderzoeksschool Caphri, “Krachtig en kwetsbaar. Onderzoek naar de
ervaringen met arbeidsparticipatie en sociale participatie van mensen met chronische ziekten en
beperkingen,” Universiteit Maastricht, Jan. 2014.
[97]H. B. Radtke, C. D. Sebold, C. Allison, J. L. Haidle, and G. Schneider, “Neurofibromatosis Type 1 in Genetic
Counseling Practice: Recommendations of the National Society of Genetic Counselors,”
J. Genet. Couns.
,
vol. 16, no. 4, pp. 387–407, Jul. 2007.
[98] S. P. Chetty, B. L. Shaffer, and M. E. Norton, “Management of pregnancy in women with genetic
disorders: Part 2: Inborn errors of metabolism, cystic fibrosis, neurofibromatosis type 1, and Turner
syndrome in pregnancy,”
Obstet. Gynecol. Surv.
, vol. 66, no. 12, pp. 765–776, 2011.
[99]A. R. Terry, F. G. Barker, L. Leffert, B. T. Bateman, I. Souter, and S. R. Plotkin, “Neurofibromatosis type 1
and pregnancy complications: a population-based study,”
Am. J. Obstet. Gynecol.
, vol. 209, no. 1, pp.
46.e1–46.e8, Jul. 2013.
[100] TNO, “Opsporing visuele stoornissen. JGZ-richtlijn.” 2010.
[101] RIVM, “Vroegsignalering van psychosociale problemen. JGZ-richtlijn.” 20008.
[102] TNO, “JGZ-richtlijn Huidafwijkingen.” 2012.
[103] TNO, “JGZ-richtlijn Signalering en verwijscriteria bij kleine lichaamslengte.” 2010.
[104] JGZ, “Handreiking Uniforme signalering van taalachterstanden bij jonge kinderen.” mei-2013.
[105] NIH, “National Institutes of Health Consensus Development Conference Statement:
neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987,”
Neurofibromatosis
, vol. 1, no. 3, pp. 172–178,
1988.
[106] R. E. Ferner, S. M. Huson, N. Thomas, C. Moss, H. Willshaw, D. G. Evans, M. Upadhyaya, R. Towers,
M. Gleeson, C. Steiger, and A. Kirby, “Guidelines for the diagnosis and management of individuals with
neurofibromatosis 1,”
J Med Genet
, vol. 44, no. 2, pp. 81–8, 2007.
[107] K. N. Shah, “The diagnostic and clinical significance of café-au-lait macules,”
Pediatr. Clin. North Am.
,
vol. 57, no. 5, pp. 1131–1153, Oct. 2010.
[108] E. M. Burkitt Wright, E. Sach, S. Sharif, O. Quarrell, T. Carroll, R. W. Whitehouse, M. Upadhyaya, S. M.
Huson, and D. G. R. Evans, “Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings
in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis,”
J. Med. Genet.
,
Jun. 2013.
[109] S. M. Huson, “The Neurofibromatoses: Differential Diagnosis and Rare Subtypes - Springer,” in
Neurofibromatoses in Clinical Practice
, London: Springer-Verlag, 2011, pp. 71–122.